In 2023, the scale of the traditional Chinese medicine formula granule industry will exceed 50 billion, and related companies have recently attracted attention

The traditional Chinese medicine formula granule is a new type of medicine with unified specification, unified dosage and unified quality standard, which is made from traditional Chinese medicine decoction pieces as raw materials, through extraction, separation, concentration, drying, granulation, packaging and other production processes
.
Compared with traditional Chinese medicine, traditional Chinese medicine formula granules have the advantages of no decoction, convenient carrying and storage, safety and hygiene, etc.
, and can meet the modern fast-paced life, so they are favored by the market
.
In terms of market space, traditional Chinese medicine formula granules are not affected by consistency evaluation, the two-invoice system and the reduction of the proportion of drugs, and are supported by a series of favorable policies, and their market is growing
.
Especially since November 1, 2021, the pilot work of traditional Chinese medicine formula granules for more than 20 years has ended, which means that all qualified traditional Chinese medicine enterprises can produce traditional Chinese medicine formula granules only by filing, which will attract more enterprises to enter the market.
will continue to expand
.
According to data from the Ministry of Industry and Information Technology, the market size of traditional Chinese medicine formula granules in 2020 is about 53.
3 billion yuan
.
Institutions generally believe that the traditional Chinese medicine formula granule industry will maintain rapid growth in the future, and by 2023, the industry scale is expected to exceed 50 billion yuan
.
In recent years, in response to the chaos in the traditional Chinese medicine market, China is also accelerating the "standardization" construction of traditional Chinese medicine.
At present, two batches of formula granules have been announced, with a total of 196 national standard varieties
.
The industry believes that the "model" of traditional Chinese medicine formula granules is of great significance to the construction of "standardization" of traditional Chinese medicine, which is conducive to bringing direction and guidance to the modernization of traditional Chinese medicine
.
In addition, with the improvement of the quality standards of domestic traditional Chinese medicine formula granules, China's formula granules are also expected to participate in the international market competition
.
In the face of the considerable and accelerated standardized development of the traditional Chinese medicine formula granules market, related companies have attracted the attention of the industry
.
It is understood that there are about 80 enterprises that have obtained the pilot qualification of traditional Chinese medicine formula granules, including Jilin Aodong, Xiangxue Pharmaceutical, Essence Pharmaceutical, Taiji Group, Jiuzhoutong, Yiling Pharmaceutical, Panlong Pharmaceutical, Kunyao Group, Tasly , Xintian Pharmaceutical, Foci Pharmaceutical, Yibai Pharmaceutical, Zhenbaodao, Yan'an Bikang and other listed pharmaceutical companies all have layouts in the field of traditional Chinese medicine formula granules
.
Recently, the layout of traditional Chinese medicine companies including Jingyuetang, Liuyao Co.
, Ltd.
, and Kangyuan Pharmaceutical Co.
, Ltd.
in traditional Chinese medicine formula granules has attracted the attention of investors
.
For example, Liuyao Co.
, Ltd.
stated on the interactive platform on March 14 that the company's traditional Chinese medicine formula granules project has obtained a drug production license and is ready for production.
It has started product filing and will be launched in the near future
.
On March 8, Kangyuan Pharmaceutical stated on the investor interaction platform that by 2021, the company has carried out research on the production process and quality standards of nearly 400 varieties of traditional Chinese medicine formula granules, formed stable process and quality standards, and completed production verification.

.
The company has coordinated and arranged production lines, business personnel, etc.
, and is actively promoting the filing work in accordance with the regulatory policies of the Jiangsu Provincial Drug Administration on traditional Chinese medicine formula granules
.
In addition, Zhenong Co.
, Ltd.
also responded to investors on the interactive platform recently, saying that the company has a number of cooperatively developed or self-built Chinese herbal medicine planting bases; more than 500 cooperative medical institutions of traditional Chinese medicine formula granules, including more than 100 medical institutions of second-level and above home
.
The industry pointed out that on the road of high-quality development of traditional Chinese medicine, the scientific planting of Chinese medicinal materials is very important
.
At present, leading Chinese medicine companies including Hongri Pharmaceutical, Yunnan Baiyao, and Buchang Pharmaceutical have all promoted the process of "standardization" of Chinese herbal medicines by jointly building and sharing Chinese herbal medicine bases
.
Taking Hongri Pharmaceutical as an example, the company is currently collaborating to build more than 100 drug source bases, and is connected to the whole-process traceability system to quickly confirm the information content of Chinese herbal medicine production, quality inspection, authenticity and so on
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.